Skip to main content

Table 1 Treatment relevant outcomes

From: Treating anxiety after stroke (TASK): the feasibility phase of a novel web-enabled randomised controlled trial

 

T0 Baseline (pre-randomisation)

T1 follow-up (~ week 6)

T2 follow-up primary endpoint (~ week 20)

Demographics

*

  

Diagnosis (stroke or TIA)

*

  

Past history of anxiety or depression

*

  

Medications for anxiety or mood

*

  

mRS

*

*

*

EQ5D5L-VAS

*

*

*

GAD-7

*

*

*

PHQ-2

*

*

*

Modified FQ

*

*

*

Single question on concurrent treatment for mood or anxiety (drug or non-drug)

*

*

*

User feedback survey

  

*

Sub study of wearing a smartwatch

 Smartwatch for measuring rest/activity

Continuous monitoring throughout the trial from T0 to T2

  1. mRS modified Rankin Scale, EQ5D5L-VAS EuroQol-5D5L-Visual analogue score, GAD-7 7-item generalised anxiety disorder questionnaire, PHQ-2 2-item Patient Health Questionnaire, FQ fear questionnaire